Aldevron Breakthrough Blog

Aldevron capacity, capability growth key to gene, cell and protein therapeutics research

0319-GEN-logoAldevron is "Driven by a Passion to Enable Science," as featured in the April Genetic Engineering & Biotechnology News. This article spans our new production facility in Fargo, North Dakota, and the expansion of our Freiburg, Germany, antibody facility, to our expanding CRISPR options, the publication discusses our ongoing push to help researchers in their work.

One particular highlight is the discussion of our new CRISPR options, including GMP level SpyFiTM Cas9 Nuclease and the availability of in-stock GMP level prepacked CRISPR nucleases.

Read More

A successful and inspiring Breakthrough Symposium

Earlier this month Aldevron hosted its first scientific conference, the Breakthrough Symposium. We felt the time was right, given 2018 is Aldevron’s 20th anniversary, to invite those in the gene and cell therapy fields to Fargo, North Dakota, for collaboration, networking and fellowship. We were overwhelmed and gratified by the response!

Read More

Aldevron Honored by Goldman Sachs for Entrepreneurship

Michael Chambers, Founder and CEO, Among 100 Most Intriguing Entrepreneurs at 2018 Builders + Innovators Summit

Goldman Sachs (NYSE:GS) is recognizing Aldevron CEO and Founder Michael Chambers as one of the 100 Most Intriguing Entrepreneurs at the 2018 Builders + Innovators Summit in Santa Barbara, California.

Read More

Taking biotech as far as it can go at the Breakthrough Symposium

Aldevron is privileged to work with some of the most innovative and groundbreaking companies, academic institutions, and government laboratories in biotechnology today. Since the company’s founding 20 years ago, Michael Chambers and John Ballantyne have always focused on clients, with the goal to improve the lives of the customers and patients they serve. Researchers across the globe are making tremendous breakthroughs in gene and cell therapy and gene editing, resulting in advances in medicine, agriculture, energy and many other fields. We are honored to serve as the basis for many of these transformative products.

Read More

Advancing therapies with mRNA

The idea of using messenger RNA (mRNA) as a drug or vaccine has interested scientists for decades. It transiently passes genetic information to the protein factories inside our cells, and can be engineered to tell this machinery what to make to fight, or prevent, disease.

Read More

Aldevron, Sanford Health, North Dakota State University highlight advances in rare disease treatment

Area organizations Aldevron, Sanford Health, and North Dakota State University (NDSU) have joined forces to bring together a special event titled, "From the Valley to the Mountain: The RARE Impact of the Red River Valley," on Wednesday, April 11 from 5:30-8 p.m. at Aldevron corporate headquarters, 4837 Amber Valley Parkway, Fargo N.D. The evening will start with refreshments, a Meet and Greet, and a silent auction, followed by leaders in science and medicine from the Red River Valley sharing their contributions toward advancing gene therapy and rare disease research efforts around the world.

Read More